Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak.

Jianhua You, Jiaxin Tian, Haidi Wu, Wenyan Kang, Jianru Wen,Hongwei Xu, Wenbo Shi,Zhi Wang, Hanyu Wei, Yanjun Du,Xiang Li, Guangyuan Mu,Min Zhou,Zhidong Gu,Jieming Qu

Expert review of anti-infective therapy（2023）

引用 0|浏览2

暂无评分

摘要

Tixagevimab/cilgavimab may have protected high-risk populations against infection with the Omicron variant, hospitalization and severe disease during the China COVID-19 pandemic.

查看译文

关键词

COVID-19, Omicron, monoclonal antibodies, tixagevimab-cilgavimab, SARS-CoV-2

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要